| Reversal of indoleamine 2, 3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme TA Triplett, KC Garrison, N Marshall, M Donkor, J Blazeck, C Lamb, ... Nature biotechnology 36 (8), 758-764, 2018 | 231 | 2018 |
| Functional genomics via CRISPR–Cas K Ford, D McDonald, P Mali Journal of molecular biology 431 (1), 48-65, 2019 | 80 | 2019 |
| Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma JS Paradis, M Acosta, R Saddawi-Konefka, A Kishore, S Lubrano, ... Clinical Cancer Research 27 (11), 3190-3200, 2021 | 46 | 2021 |
| Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange W Kelton, AC Waindok, T Pesch, M Pogson, K Ford, C Parola, ST Reddy Scientific reports 7 (1), 45775, 2017 | 23 | 2017 |
| Noncoding RNA in Liver Regeneration—From Molecular Mechanisms to Clinical Implications O Sergeeva, E Sviridov, T Zatsepin Seminars in Liver Disease 40 (01), 070-083, 2020 | 12 | 2020 |
| Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme J Blazeck, CS Karamitros, K Ford, C Somody, A Qerqez, K Murray, ... Nature catalysis 5 (10), 952-967, 2022 | 9 | 2022 |
| Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors KM Ford, R Panwala, DH Chen, A Portell, N Palmer, P Mali Cell systems 12 (7), 716-732. e7, 2021 | 9 | 2021 |
| Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures M Hu, XY Lei, JD Larson, M McAlonis, K Ford, D McDonald, K Mach, ... Biomaterials 280, 121276, 2022 | 5 | 2022 |
| Rna and dna base editing via engineered adar recruitment P Mali, D Katrekar, D Meluzzi, G Chen, KM Ford US Patent App. 17/273,885, 2022 | 4 | 2022 |
| Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma JS Paradis, M Acosta, R Saddawi-Konefka, A Kishore, S Lubrano, ... Clinical Cancer Research 27 (16), 4664-4664, 2021 | 2 | 2021 |
| An analysis of firefighter personal safety alarm effectiveness on the fire ground K Ford, M Habeeb, J Suits, M Abbasi, PS Wilson, O Ezekoye The Journal of the Acoustical Society of America 134 (5_Supplement), 4094-4094, 2013 | 2 | 2013 |
| Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation K Ford, BP Munson, SH Fong, R Panwala, WK Chu, J Rainaldi, ... Scientific reports 13 (1), 7678, 2023 | | 2023 |
| Interface-guided phenotyping of coding variants in the transcription factor RUNX1 with SEUSS K Ozturk, R Panwala, J Sheen, K Ford, N Payne, DE Zhang, S Hutter, ... bioRxiv, 2023.08. 03.551876, 2023 | | 2023 |
| A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC Y Goto, K Koshizuka, T Ando, H Izumi, X Wu, K Ford, X Feng, Z Wang, ... bioRxiv, 2023.08. 07.552216, 2023 | | 2023 |
| Gene fragment overexpression screening methodologies, and uses thereof P Mali, KM Ford, N Palmer, R Panwala US Patent App. 17/638,428, 2022 | | 2022 |
| Reprogramming Adeno-Associated Virus Tropism Via Displayed Peptides Tiling Receptor-Ligands A Portell, KM Ford, A Suhardjo, J Rainaldi, MN Bublik, M Sanghvi, ... bioRxiv, 2022.09. 26.509383, 2022 | | 2022 |
| Mapping and Targeting Genetic and Physical Interactions at Scale K Ford UC San Diego, 2022 | | 2022 |
| Systematic mapping of genetic interactions in human cancer cells reveals context dependent cancer signaling pathways SH Fong, BM Kuenzi, J Lee, K Sanchez, A Bojorquez-Gomez, K Ford, ... Cancer Research 81 (13_Supplement), 2133-2133, 2021 | | 2021 |
| Using physical, genetic and integrated cancer cell maps to investigate head and neck cancer and breast cancer JF Kreisberg, F Zheng, S Fong, BM Kuenzi, K Ford, D Swaney, M Kim, ... Cancer Research 80 (16_Supplement), 223-223, 2020 | | 2020 |
| Development of a Kynureninase Clinical Candidate, a First-in-Class Enzymatic Checkpoint Inhibitor J Blazeck, C Somody, A Qerqez, K Ford, K Garrison, C Karamitros, ... 2018 AIChE Annual Meeting, 2018 | | 2018 |
